AUTODOC
Autodoc, Europe’s largest online retailer of car spare parts, is donating EUR 50,000 to the Stiftung Universitätsmedizin Essen foundation to support the fight against COVID-19. The researchers are studying the biology of the virus together with Chinese colleagues in a laboratory in Wuhan, China. The aim is to develop therapeutic options and preventive measures. As an internationally active company, Autodoc would like to become involved at a global level in the fight against the current pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005597/en/
Autodoc GmbH, based in Berlin, is an international company with online shops in 26 European countries. The employees come from all over the world. The current crisis also affects Autodoc employees, customers and suppliers to a high degree. Autodoc would like to take its responsibility as a company and actively participate in the fight against COVID-19. To this end, Autodoc is supporting researchers at the Universitätsmedizin Essen medical center and the Union Hospital in Wuhan in their search for special treatments against the virus.
According to Alexej Erdle, managing partner of Autodoc GmbH, “The corona crisis is a global pandemic that affects us all. We are an international company. That is why we feel a clear responsibility here to contribute to solving this crisis. Every day we see what can be achieved when people from different countries work together, just as the researchers from Essen and Wuhan are doing. Supporting their work is now the best way for us to do something that helps people all over the world, i.e. to fight this pandemic. With this donation, we want to set an example so that every individual as well as every company can think about how to get involved within the scope of their respective possibilities so that we can succeed in overcoming this challenge together.
Researchers against a global pandemic
Since the end of December 2019, the novel coronavirus, SARS-CoV-2, has been spreading at high speed. It is the trigger of the COVID-19 disease. The Institute of Virology and the Clinic for Infectiology at the Universitätsmedizin Essen medical center and the Clinic for Infectious Diseases at the Union Hospital in Wuhan have been working closely together for many years. In 2017, a joint research laboratory was founded in Wuhan. Numerous data and samples have been collected and recorded there since the beginning of the COVID-19 pandemic. Due to the number of cases in China, this results in a much larger database than is currently the case in Germany, for example. The laboratory is already in operation and well equipped, but money is still urgently needed to cover the running costs for material and personnel. Autodoc is now supporting the researchers’ work with a sum of EUR 50,000.
Jorit Ness, Managing Director of the University Medical Foundation, is very grateful for the support: “In the current situation, rapid help – which is at the same time sustainable – is essential. Thanks to the research cooperation between Essen and Wuhan, which has been in place for years, professional and established structures are now in place and can be used immediately. It is now important to make additional funds available for the evaluation of the extraordinarily large amounts of data and samples of disease cases. With the donation from Autodoc GmbH we have come a big step closer to our goal”.
Social commitment
Since its foundation in 2008, Autodoc has seen itself as an active part of society and is committed both ideologically and financially to helping disadvantaged social groups. Autodoc therefore regularly supports local initiatives in various European countries.
If you would like to support the research work in Essen and Wuhan, please visit https://www.universitaetsmedizin.de/forschung/corona/ and make a donation online. Or donate directly to:
Stiftung Universitätsmedizin Essen
Hufelandstraße 55
45147 Essen, Germany
E-mail: info@universitaetsmedizin.de
Internet: https://www.universitaetsmedizin.de/
Donation account:
IBAN: DE 0937 0205 0005 0005 0005
BIC: BFSWDE33
Reference: corona research
Autodoc GmbH – a brief profile
Autodoc GmbH is Europe’s leading online dealer for automotive spare parts. As the fastest-growing company in this sector with a 63% growth in turnover in the 2018 financial year to around EUR 415 million (2017: EUR 254 million), Autodoc is aiming to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media activities, technical support in the respective national language and demand-oriented product range composition with currently almost 2.5 million products from 545 brand manufacturers for 128 car brands. The online retailer offers a wide range of products from brake systems, body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heaters, repair kits and engine oil. In June 2018, the company celebrated its tenth anniversary. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In May 2019, the company opened a representative office on Kurfürstendamm in addition to its headquarters.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG’s MidOcean Energy Completes Acquisition of Interest in Canada from PETRONAS17.12.2025 09:58:00 CET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its acquisition of a 20% interest in PETRONAS’ key entities in Canada. The transaction includes a 20% interest in the North Montney Upstream Joint Venture (“NMJV”), which holds PETRONAS’ upstream investment in Canada, and a 20% interest in the North Montney LNG Limited Partnership (“NMLLP”), which holds PETRONAS’ 25% participating interest in the LNG Canada Project. This strategic investment positions MidOcean across the LNG value chain, securing upstream resources and downstream liquefaction through the LNG Canada Project, with around 0.7 MTPA of associated LNG and potential to grow further. RBC Capital Markets acted as financial advisor to MidOcean, and Latham & Watkins acted as legal advisor. About EIG EIG is a leading institutional investor in the global energy and infrastru
Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 09:00:00 CET | Press release
Nexo has signed a landmark multi-year deal with Tennis Australia, covering the Australian Open and the Summer of Tennis. The partnership delivers exclusive experiences, including a feature in the Coachеs Pod. The announcement continues Nexo’s rapid global expansion, following three other major sports partnerships in 2025. Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founde
Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 08:00:00 CET | Press release
The strategic funding from international investment firm Vitruvian Partners will advance the company’s platform, helping organizations rapidly transform threat data into decisive action and a more robust security posture. Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, postu
VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 08:00:00 CET | Press release
VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press release
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as 48 hours after initial treatment and steadily increased through to Day 141 Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signalling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in atopic dermatitis and prurigo nodularis2-4 Nemolizumab is approved by multiple regulatory authorities around the world for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, including in the U.S. and EU5,6 Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom